Table 2.
ASHG | ACMG (2008) | NSGC | FDA/FTCa | Set 1 practices | Set 2 practices | |
---|---|---|---|---|---|---|
General information | ||||||
disclose which genes are tested | + | + | ||||
disclose which polymorphisms are tested | + | |||||
Pre-test counseling | ||||||
provide guidance on indications for testing | + | + | + | |||
describe benefits of testing | + | + | + | + | + | |
describe risks of testing | + | + | + | + | ||
Laboratory | ||||||
laboratory is CLIA certified | + | + | + | + | + | + |
Post-test counseling | ||||||
provide information on test limitations | + | + | + | + | + | |
provide information on clinical validity | + | + | + | |||
allow consumer to call with questions | + | |||||
refer consumer to their doctor | + | + | + | + | ||
assist consumer with obtaining a doctor | + | + | ||||
refer to another source of information | + | + | ||||
Privacy protections | ||||||
provide written privacy policy | + | + | + | + | ||
Total practices | 6 | 4 | 6 | 6 | 13 | 7 |
Recommendations in the FTC fact sheet were consumer-oriented rather than company-oriented.